Query: Analysis of pharmacokinetic and tissue distribution profiles of candidate small molecules with potential to cross the blood–nerve barrier and accumulate in peripheral nerve tissues, including safety and tolerability data in non-human primates or human Phase I trials

Candidate small molecules designed to cross the blood–nerve barrier (BNB) and accumulate in peripheral nerve tissues must exhibit distinct pharmacokinetic (PK) and tissue distribution profiles that balance effective target engagement with acceptable safety margins. In preclinical studies, methodologies such as the Combinatory Mapping Approach for CIPN (CMA-CIPN) have been developed to quantify unbound extracellular (Kp,uu) and intracellular (Kp,uu,cell) concentration ratios in relevant nerve tissues, including the dorsal root ganglia (DRG) and sciatic nerve (SN) as well as non-conventional sites like skeletal muscle. These studies demonstrate that CIPN-positive drugs such as paclitaxel and vincristine display time-dependent accumulation combined with significant intracellular uptake, whereas drugs not associated with neuropathy, such as nilotinib and methotrexate, show limited penetration and no notable intracellular accumulation (hu2024analysisofthe pages 1-2, hu2024analysisofthe pages 2-4).

The mechanistic basis for these differences is closely related to the ability of the molecules to traverse both endothelial and parenchymal cellular barriers. Transport across highly selective barriers, including the blood–dorsal root ganglion barrier and blood–nerve barrier, is modulated by passive diffusion and active transporter activities. The studies underscore that localized retention—both in extracellular and intracellular compartments—is a key predictor of neurotoxicity, suggesting that a high unbound drug concentration in these compartments predisposes to chemotherapy-induced peripheral neuropathy (CIPN) (hu2024analysisofthe pages 1-2, hu2024analysisofthe pages 4-5).

Additional support comes from investigations into BNB permeability in inflammatory conditions. Research in experimental autoimmune neuritis (EAN) shows that under conditions of neuroinflammation, the BNB becomes compromised, enabling small molecules and nanoparticles—especially those near or below ~69 kDa—to cross the barrier more readily. This size-dependent permeability, coupled with endothelial activation and increased intercellular junction separation, allows targeted drug delivery to peripheral nerve tissues (langert2025bloodnervebarrier pages 1-2, langert2025bloodnervebarrier pages 2-3).

Complementary findings emphasize the importance of molecular properties such as lipophilicity and the ability to exploit receptor-mediated transport mechanisms. Strategies including prodrug modifications and nanoparticle encapsulation have been proposed to improve passive diffusion and enhance retention within nerve tissues, drawing parallels with drug delivery approaches across the blood–brain barrier (BBB) (sun2023drugpermeabilityfrom pages 16-18, sun2023drugpermeabilityfrom pages 18-19).

Sustained accumulation in peripheral nerve tissues has also been observed in rodent models. For instance, studies tracking microtubule-binding chemotherapy agents like paclitaxel indicate rapid distribution into the DRG and SN with prolonged tissue residency relative to plasma clearance. This sustained presence correlates with neurotoxic effects and highlights the critical nature of tissue-specific PK profiling when evaluating neurotoxicity risk (wozniak2016sustainedaccumulationof pages 2-3).

Safety and tolerability data, although limited, have been obtained using non-human primate models and early-phase human trials. For example, venom-derived peptide agents targeting NaV1.7 sodium channel subtypes, such as Tsp1a conjugates, have demonstrated strong fluorescent nerve imaging signals without adverse cardiac or skeletal muscle effects in non-human primates (chow2024shiningalight pages 11-13). Moreover, a phase 0 clinical trial with AR-42—a histone deacetylase inhibitor—provided evidence of tissue uptake in peripheral nerve tumors along with biochemical biomarker modulation, indicating that sufficient drug concentrations can be achieved in target tissues while maintaining a tolerable safety profile (NCT02282917, Clinical Trials Search: blood-nerve barrier AND small molecule AND peripheral nerve AND (phase 1 OR non-human primate OR safety OR tolerability)).

Formulation-dependent differences further influence drug distribution profiles. Studies indicate that modifications in drug formulation can alter paclitaxel’s distribution to relevant anatomical sites and modify its PK profile, suggesting that optimizing formulation may mitigate CIPN risk (girdenyte2024formulationdependentdifferencesin pages 14-14). Additionally, mathematical models predict that local tissue drug distribution is influenced by diffusion parameters and barrier integrity, supporting the importance of a comprehensive PK approach that integrates both experimental and computational methods (laranjeira2023perspectivesonoptimizing pages 14-16).

In summary, candidate small molecules that effectively cross the BNB require careful optimization of physicochemical properties, barrier transport mechanisms, and formulation strategies to ensure therapeutic efficacy while minimizing peripheral neurotoxicity. Preliminary safety and tolerability findings from non-human primate studies and early-phase human trials are promising; however, further investigations are necessary to fully delineate risk-benefit profiles for clinical application.

References:
1. (hu2024analysisofthe pages 1-2): Yang Hu, Milda Girdenyté, Lieke Roest, Iida Liukkonen, Maria Siskou, Frida Bällgren, Margareta Hammarlund-Udenaes, and Irena Loryan. Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy. Fluids and Barriers of the CNS, Feb 2024. URL: https://doi.org/10.1186/s12987-024-00519-7, doi:10.1186/s12987-024-00519-7. This article has 7 citations and is from a peer-reviewed journal.

2. (hu2024analysisofthe pages 2-4): Yang Hu, Milda Girdenyté, Lieke Roest, Iida Liukkonen, Maria Siskou, Frida Bällgren, Margareta Hammarlund-Udenaes, and Irena Loryan. Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy. Fluids and Barriers of the CNS, Feb 2024. URL: https://doi.org/10.1186/s12987-024-00519-7, doi:10.1186/s12987-024-00519-7. This article has 7 citations and is from a peer-reviewed journal.

3. (hu2024analysisofthe pages 4-5): Yang Hu, Milda Girdenyté, Lieke Roest, Iida Liukkonen, Maria Siskou, Frida Bällgren, Margareta Hammarlund-Udenaes, and Irena Loryan. Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy. Fluids and Barriers of the CNS, Feb 2024. URL: https://doi.org/10.1186/s12987-024-00519-7, doi:10.1186/s12987-024-00519-7. This article has 7 citations and is from a peer-reviewed journal.

4. (langert2025bloodnervebarrier pages 1-2): Kelly Langert, Chanpreet Kaur, Ellaina Villarreal, and Maleen Cabe. Blood nerve barrier permeability enables nerve targeting of circulating nanoparticles in experimental autoimmune neuritis. Unknown journal, Jun 2025. URL: https://doi.org/10.21203/rs.3.rs-4631228/v1, doi:10.21203/rs.3.rs-4631228/v1.

5. (langert2025bloodnervebarrier pages 2-3): Kelly Langert, Chanpreet Kaur, Ellaina Villarreal, and Maleen Cabe. Blood nerve barrier permeability enables nerve targeting of circulating nanoparticles in experimental autoimmune neuritis. Unknown journal, Jun 2025. URL: https://doi.org/10.21203/rs.3.rs-4631228/v1, doi:10.21203/rs.3.rs-4631228/v1.

6. (sun2023drugpermeabilityfrom pages 16-18): Yifei Sun, Mahmood Zabihi, Qi Li, Xiaosi Li, Brandon J. Kim, Eroboghene E. Ubogu, Srinivasa N. Raja, Ursula Wesselmann, and Chao Zhao. Drug permeability: from the blood–brain barrier to the peripheral nerve barriers. Advanced Therapeutics, Feb 2023. URL: https://doi.org/10.1002/adtp.202200150, doi:10.1002/adtp.202200150. This article has 20 citations and is from a peer-reviewed journal.

7. (sun2023drugpermeabilityfrom pages 18-19): Yifei Sun, Mahmood Zabihi, Qi Li, Xiaosi Li, Brandon J. Kim, Eroboghene E. Ubogu, Srinivasa N. Raja, Ursula Wesselmann, and Chao Zhao. Drug permeability: from the blood–brain barrier to the peripheral nerve barriers. Advanced Therapeutics, Feb 2023. URL: https://doi.org/10.1002/adtp.202200150, doi:10.1002/adtp.202200150. This article has 20 citations and is from a peer-reviewed journal.

8. (wozniak2016sustainedaccumulationof pages 2-3): Krystyna M. Wozniak, James J. Vornov, Ying Wu, Kenichi Nomoto, Bruce A. Littlefield, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman, Nancy Wong, and Barbara S. Slusher. Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: correlations with time course and neurotoxic severity. Cancer Research, 76:3332-3339, May 2016. URL: https://doi.org/10.1158/0008-5472.can-15-2525, doi:10.1158/0008-5472.can-15-2525. This article has 53 citations and is from a highest quality peer-reviewed journal.

9. (NCT02282917): D. Bradley Welling, MD, PhD. Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma. Massachusetts Eye and Ear Infirmary. 2015. ClinicalTrials.gov Identifier: NCT02282917

10. (chow2024shiningalight pages 11-13): Chun Yuen Chow and Glenn F. King. Shining a light on venom-peptide receptors: venom peptides as targeted agents for in vivo molecular imaging. Toxins, 16:307, Jul 2024. URL: https://doi.org/10.3390/toxins16070307, doi:10.3390/toxins16070307. This article has 1 citations and is from a peer-reviewed journal.

11. (girdenyte2024formulationdependentdifferencesin pages 14-14): Milda Girdenytė, Yang Hu, Aghavni Ginosyan, Margareta Hammarlund-Udenaes, and Irena Loryan. Formulation-dependent differences in paclitaxel distribution to anatomical sites relevant to chemotherapy-induced peripheral neuropathy. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1486686, doi:10.3389/fphar.2024.1486686. This article has 1 citations and is from a peer-reviewed journal.

12. (laranjeira2023perspectivesonoptimizing pages 14-16): Simao Laranjeira, Victoria H. Roberton, James B. Phillips, and Rebecca J. Shipley. Perspectives on optimizing local delivery of drugs to peripheral nerves using mathematical models. WIREs Mechanisms of Disease, Jan 2023. URL: https://doi.org/10.1002/wsbm.1593, doi:10.1002/wsbm.1593. This article has 3 citations.
